Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
04 avr. 2024 06h45 HE
|
Achilles Therapeutics PLC
– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols...
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
04 avr. 2024 06h30 HE
|
Achilles Therapeutics PLC
– Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – First...
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
05 févr. 2024 07h00 HE
|
Achilles Therapeutics PLC
LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal...
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction
18 déc. 2023 07h00 HE
|
Achilles Therapeutics PLC
LONDON, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal...
Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
13 nov. 2023 16h30 HE
|
Achilles Therapeutics PLC
– On track to dose 15-20 patients with higher dose cNeT by year-end 2023 – – Clinical and translational science data update from the ongoing Phase I/IIa trials in NSCLC and melanoma expected in Q1...
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
22 sept. 2023 16h30 HE
|
Achilles Therapeutics PLC
LONDON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal...
Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
04 août 2023 07h00 HE
|
Achilles Therapeutics PLC
- Clinical and translational science data expected in the fourth quarter of 2023 from the ongoing Phase I/IIa trials in NSCLC and melanoma - - neoRanker™ immunogenicity prediction module of PELEUS™...
Achilles Therapeutics to Present at Upcoming Conferences
12 juin 2023 08h00 HE
|
Achilles Therapeutics PLC
LONDON, June 12, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors,...
Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
10 mai 2023 07h15 HE
|
Achilles Therapeutics PLC
- Phase I/IIa clinical trials in NSCLC and melanoma progressing with additional clinical and translational science data expected in the fourth quarter of 2023 - - Strong cash position of $158.5...
Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens
10 mai 2023 07h00 HE
|
Achilles Therapeutics PLC
LONDON, May 10, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal...